Endometrial cancer prediction model, endometrial cancer diagnostic kit and application of endometrial cancer prediction model and endometrial cancer diagnostic kit

Through the detection of supernatant of uterine microcell suspension and biomarker prediction model, the non-invasive, minimally invasive, high positive predictive values ​​and economical and simple problems of early screening of endometrial cancer are solved, and the efficiency of endometrial cancer is achieved Early diagnosis and screening significantly improve patient survival and treatment effect.

CN118937679APending Publication Date: 2024-11-12SHANGHAI FIRST MATERNITY & INFANT HOSPITAL
View PDF 0 Cites 1 Cited by

Patent Information

Application Number
CN202411213977.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-31
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The prior art cannot effectively meet the requirements of non-invasive, minimally invasive, high positive predictive values ​​and economical simplicity of early screening of endometrial cancer, resulting in difficulty in early diagnosis and affecting patient survival and treatment difficulty.

Method used

Through the detection of uterine microcell suspension supernatant, predictive models of biomarkers such as CA125, CA153, CA199, CEA, SCC were constructed, and endometrial cancer screening diagnostic kits were developed, and risk prediction was predicted using multi-factor logistic regression analysis.

Benefits of technology

It has achieved efficient early screening of endometrial cancer, improved diagnostic accuracy and generalizability, and significantly improved patient survival and treatment effect.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118937679A_ABST
    Figure CN118937679A_ABST
Patent Text Reader

Abstract

The invention relates to an endometrial cancer prediction model for endometrial cancer high-risk groups and biomarker spectra. The endometrial cancer prediction model comprises reagents for determining the content of supernatant of uterine cavity cell suspensions of the following biomarkers: CA125, CA153, CA199, CEA and SCC. The invention also provides a biomarker combined reagent and application of the biomarker combined reagent in preparation of a kit for predicting endometrial cancer, and a sample to be detected is a reagent for measuring the content of supernatant of uterine cavity cell suspension. CA125, CA153, CA199, CEA and SCC uterine cavity cell suspension supernatant detection data are used, an endometrial cancer risk prediction model is constructed through multi-factor logistic regression analysis, the endometrial cancer screening and diagnosis kit is developed, the endometrial cancer screening and diagnosis kit has good clinical application potential in the field of endometrial cancer screening and diagnosis, the endometrial cancer prediction model is established, and the endometrial cancer screening and diagnosis kit has good clinical application potential. The bottleneck problem in the field of endometrial cancer screening is solved, and the kit is of great significance to early diagnosis and screening of endometrial cancer and has a wide clinical application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of diagnostic kits, and in particular to an endometrial cancer prediction model and an endometrial cancer diagnostic kit and application thereof. Background Art

[0002] Endometrial cancer (endometrial cancer) is one of the most common malignant tumors of the female reproductive system. The incidence of endometrial cancer in my country continues to rise and is showing a trend of younger age. According to data released by the National Cancer Center, there will be approximately 77,700 new cases of endometrial cancer in my country in 2022, and the incidence rate has increased by 3.4% from 2000 to 2018. Most patients with endometrial cancer are diagnosed and treated due to symptoms such as abnormal bleeding, but 20% of patients are still difficult to detect due to hidden symptoms. Early endometrial cancer usually has a good prognosis. The five-year survival rate of patients with endometrial cancer who are diagnosed early and treated in a standardized manner can reach more than 90%, while the five-year survival rate of patients with advanced (stage III and IV) endometrial cancer is only 10-60%. Therefore, early diagnosis is of great significance for improving the survival rate of patients with endometrial cancer, reducing the difficulty and risk of treatment, and improving prognosis, and early screening is one of the important ways to detect and diagnose endometrial cancer early.

[0003] Cancer screening refers to the process of screening high-risk groups or tumor-positive patients from a large number of asymptomatic "healthy" people by means of fast, simple and effective methods. Therefore, the screening technology needs to meet the three basic conditions of "minimally invasive or non-invasive sampling, high positive predictive value, and economical and simple". However, the serum carbohydrate antigen detection, transvaginal ultrasound examination and curettage / endometrial biopsy technology commonly used in the diagnosis of endometrial cancer in clinical practice cannot meet the above three conditions at the same time and cannot be used for screening. The concentration of carbohydrate antigens in the blood of early endometrial cancer is very low, and the sensitivity of serum carbohydrate antigen detection is low. Transvaginal ultrasound is a screening method that measures imaging features such as endometrial thickness and blood flow signals. It is non-invasive, safe and well tolerated. However, since there is no unified judgment standard for vaginal ultrasound, and the diagnosis is affected by the operator's subjective judgment and instrument errors, its specificity is only 51.5%. Most patients with high-risk factors or typical symptoms ultimately need to obtain sufficient endometrial samples through invasive methods such as hysteroscopy and curettage and perform pathological examinations to confirm endometrial cancer. However, this type of operation is traumatic and invasive, and the risks of anesthesia, lower abdominal pain, bleeding, uterine perforation, and overhydration syndrome increase, making it difficult to use as a screening method in outpatient or physical examination settings. More importantly, even in high-risk groups such as postmenopausal vaginal bleeding, only less than 10% of patients are diagnosed with endometrial cancer, and more than 90% of patients' abnormal bleeding symptoms are caused by functional reasons or benign lesions. These unnecessary invasive operations have brought huge burdens on women's physiology, psychology, and socio-economics. So far, there is still a lack of effective endometrial cancer screening technology in clinical practice. Exploring a screening method that can simultaneously meet the requirements of non-invasive or minimally invasive sampling, high positive predictive value, and economical and simple screening, and improving the accuracy and scalability of screening, has become a bottleneck problem that urgently needs to be solved in promoting the screening of endometrial cancer.

[0004] Endometrial micro-histology examination: It is a detection method that uses an endometrial sampler to take a micro-tissue sample of the endometrium, and diagnoses endometrial cancer and precancerous lesions through histopathological analysis. This method is easy to operate, does not require surgery, and can be completed in an outpatient clinic, but it has high sampling requirements and requires a more comprehensive endometrial tissue sample, including bilateral uterine horns. Insufficient sampling will lead to false negative results, and it also requires a high level of diagnostic ability from pathologists. Therefore, the promotion of this detection technology in clinical practice is relatively slow, and many pathologists refuse to use it.

[0005] Serum CA125, CA153, CA199, CEA, SCC, AFP, HE4, FRT, AST, ALP, CK, LDH, ALT, and GGT tests: Among these indicators in serum, only CA125 and HE4 have reference value for auxiliary diagnosis of endometrial cancer. The others are not specific markers for endometrial cancer. Even CA125 and HE4 are not specifically expressed in endometrial cancer, and they are also highly expressed in other tumors such as ovarian cancer. Summary of the invention

[0006] The purpose of the present invention is to provide an endometrial cancer prediction model and an endometrial cancer diagnosis kit and application in view of the deficiencies in the prior art.

[0007] In a first aspect, the present invention provides a high-risk population for endometrial cancer and a biomarker spectrum prediction model for endometrial cancer, including reagents for determining the content of the following biomarkers in the supernatant of uterine cell suspension: CA125, CA153, CA199, CEA and SCC.

[0008] As a preferred example, an operating instruction is included, and the operating instruction contains the following contents:

[0009] Collect the values ​​of CA125, CA153, CA199, CEA and SCC content; substitute the above values ​​into the scoring model;

[0010] logit(p)=-3.889+0.05702×SCC_tissue+0.03793×CEA_tissue-0.0001363×CA125_tissue+0.04379×CA153_tissue-0.00001058×CA199_tissue

[0011] If p>0.598, the patient is diagnosed as having endometrial cancer; otherwise, the patient is predicted to have benign endometrial lesions.

[0012] In a second aspect, the present invention provides an application of a biomarker combination reagent in the preparation of a kit for predicting endometrial cancer, wherein the biomarker consists of CA125, CA153, CA199, CEA and SCC, and the sample to be tested for the biomarker is a reagent containing the supernatant content of a uterine cavity cell suspension.

[0013] As a preferred example, the biomarker test sample is a reagent containing the supernatant content of uterine cavity cell suspension of a high-risk population for endometrial cancer.

[0014] In a third aspect, the present invention provides a kit for predicting endometrial cancer, the kit containing a biomarker combination reagent, wherein the biomarker consists of CA125, CA153, CA199, CEA and SCC, and the sample to be tested for the biomarker is a reagent containing the supernatant content of a uterine cavity cell suspension.

[0015] As a preferred example, the biomarker test sample is a reagent containing the supernatant content of uterine cavity cell suspension of a high-risk population for endometrial cancer.

[0016] In a fourth aspect, the present invention provides an application of a biomarker combination reagent in the preparation of a kit for distinguishing endometrial cancer from benign endometrial lesions, wherein the biomarker consists of SCC, CEA, CA199, CA153 and CA125, and the sample to be tested for the biomarker is a reagent containing the supernatant content of a uterine cavity cell suspension.

[0017] As a preferred example, the biomarker test sample is a reagent containing the supernatant content of uterine cavity cell suspension of a high-risk population for endometrial cancer.

[0018] In a fifth aspect, the present invention provides a kit for distinguishing endometrial cancer from benign endometrial lesions, the kit containing a biomarker combination reagent, the biomarker consisting of SCC, CEA, CA199, CA153 and CA125, and the sample to be tested for the biomarker is a reagent containing the supernatant content of a uterine cavity cell suspension.

[0019] As a preferred example, the biomarker sample to be tested is a reagent for the supernatant content of uterine cell suspension of a high-risk population for endometrial cancer, and includes an operating instruction, which records the following contents:

[0020] Collect the values ​​of CA125, CA153, CA199, CEA and SCC content; substitute the above values ​​into the scoring model;

[0021] logit(p)=-3.889+0.05702×SCC_tissue+0.03793×CEA_tissue-0.0001363

[0022] ×CA125_tissue+0.04379×CA153_tissue-0.00001058×CA199_tissue

[0023] If p>0.598, the patient is diagnosed as having possible endometrial cancer; otherwise, the patient is predicted to have benign endometrial lesions.

[0024] The advantages of the present invention are: to fill the gap in endometrial cancer screening technology, a "uterine cavity micro-cell suspension supernatant detection" method was created, and based on the detection method, it was found that the content of CA125, CA153, CA199, CEA, and SCC in the uterine cavity micro-cell suspension supernatant of the endometrial cancer group was significantly higher than that of the endometrial benign lesion group, which has predictive value. On this basis, we used CA125, CA153, CA199, CEA, and SCC uterine cavity cell suspension supernatant detection data to construct an endometrial cancer risk prediction model through multi-factor logistic regression analysis, and developed an endometrial cancer screening diagnostic kit, which showed good clinical application potential in the field of endometrial cancer screening and diagnosis. The present invention establishes an endometrial cancer prediction model, solves the bottleneck problem in the field of endometrial cancer screening, is of great significance to the early diagnosis and screening of endometrial cancer, and has broad prospects for clinical application. BRIEF DESCRIPTION OF THE DRAWINGS

[0025] Figure 1 : ROC analysis of the endometrial cancer prediction model based on the detection of SCC, CEA, CA199, CA153 and CA125 in the supernatant of uterine cell suspension and the endometrial cancer prediction model based on the detection of SCC, CEA, CA199, CA153 and CA125 in serum. DETAILED DESCRIPTION

[0026] The present invention will be further described below in conjunction with specific embodiments. It should be understood that these embodiments are only used to illustrate the present invention and are not intended to limit the scope of the present invention. In addition, it should be understood that after reading the content of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms fall within the scope limited by the appended claims of the application equally.

[0027] Example 1

[0028] Based on the detection technology of intrauterine micro-cell suspension supernatant, the present invention carried out a cohort study of high-risk populations for endometrial cancer and successfully constructed an "endometrial cancer intrauterine screening model" with good predictive potential. The specific experimental materials, methods and results are as follows:

[0029] 1. Experimental materials, equipment and methods used in the detection of CA125, CA153, CA199, CEA, SCC and HE4 in the supernatant of intrauterine microcell suspension

[0030] 1) Experimental materials: speculum, endometrial sampler, gauze, medical alcohol, surgical scissors / forceps, sample storage tube (containing 1.5 ml of normal saline), pipette, pipette tip, ep tube, test tube; Roche Diagnostics carbohydrate antigen 125 test kit (electrochemiluminescence method), carcinoembryonic antigen test kit (electrochemiluminescence method), carbohydrate antigen 153 test kit (electrochemiluminescence method), carbohydrate antigen 199 test kit (electrochemiluminescence method), squamous cell carcinoma antigen test kit (electrochemiluminescence method), human epididymis protein 4 test kit (electrochemiluminescence method)

[0031] 2) Experimental equipment: centrifuge, clean bench, Roche Cobas e801 fully automatic electrochemiluminescence analyzer

[0032] 3) Detection method: Follow the operating instructions of the Roche Cobas e801 fully automatic electrochemiluminescence analyzer and the instructions of the Roche original matching kit, place the sample in the injection area, and click Start. After the test is completed, the instrument will automatically calculate the analyte concentration of the sample.

[0033] 4) The linear range of CA125 detection is 0.6-5000U / ml, and the linear range of CEA detection is

[0034] 0.3-1000ng / ml, the linear range of CA153 detection is 1.5-300U / ml, the linear range of CA199 detection is 2-1000U / ml, the linear range of SCC detection is 0.1-70ng / ml, and the linear range of HE4 detection is 15-1500pmol / L. For samples beyond the detection range, dilute them before testing to make the measured value within the detection linear range.

[0035] 2. Establish a high-risk cohort for endometrial cancer

[0036] 1) Patients who visited the Department of Gynecologic Oncology at Shanghai First Maternity and Infant Health Care Hospital due to abnormal vaginal bleeding or postmenopausal endometrial thickening were included in the study.

[0037] Inclusion criteria: ① no history of primary malignant tumor; ② received pathological examination in our hospital.

[0038] Exclusion criteria: ① Those who have received or are currently receiving hormone replacement therapy; ② Those who have suffered from or are concurrently suffering from thyroid dysfunction, immunodeficiency disease, gout or other diseases that may affect metabolism; ③ Those who have been taking anticoagulants, weight loss drugs, health care drugs, Chinese herbal medicines and other drugs that may affect metabolism for a long time; ④ Those who have a long-term vegetarian habit. 2) Research groups:

[0039] ① Endometrial cancer group: patients with newly diagnosed endometrial cancer diagnosed by pathology

[0040] ②Control group: patients whose pathological diagnosis excluded endometrial cancer (including proliferative / secretory endometrium, atrophic endometrium, endometrial hyperplasia, endometrial polyps, etc.).

[0041] 3) Detect CA125, CA153, CA199, CEA, SCC, and HE4 in the supernatant of uterine microcell suspension of the research subjects and collect data

[0042] 3. Construction of “Uterine Cavity Screening Model for Endometrial Cancer”

[0043] We used multivariate logistic regression analysis to construct a diagnostic model for the detection data of CA125, CA153, CA199, CEA, SCC, and HE4 in the supernatant of the uterine cavity microcell suspension of patients in the endometrial cancer group and the control group. The main goal of logistic regression is to calculate the probability that each sample belongs to a certain category by linearly combining multiple independent variables (i.e., tumor markers), thereby achieving classification prediction of the disease. We took the pathological diagnosis of endometrial cancer (malignant or benign) as the dependent variable and tumor markers as independent variables to construct multivariate logistic regression models based on blood tumor marker indicators or tissue supernatant tumor marker indicators. The performance of the model was evaluated by calculating the receiver operating characteristic curve (ROC curve) and its area under it (AUC). The analysis R code is as follows:

[0044] #Multi-factor logistic---------------------------------- data$diagnosis_num=factor(data$diagnosis_num,levels=c(0,1))

[0045] fit1<-glm(diagnosis_num~scc_b+cea_b+ca125_b+ca153_b+ca199_b,

[0046] data=data,family=binomial())

[0047] data$pre1<-predict(fit1,newdata=data,type="response")

[0048] summary(fit1)

[0049] fit2<-glm(diagnosis_num~scc_tissue+cea_tissue+ca125_tissue+ca153_tissue+ca199_tissue,

[0050] data=data,family=binomial())

[0051] data$pre2<-predict(fit2,newdata=data,type="response")

[0052] summary(fit2)

[0053] #Calculate AUC value and draw ROC curve

[0054] roc1<-roc(data$diagnosis_num,data$pre1,auc=TRUE,ci=TRUE,smooth=T)

[0055] roc2<-roc(data$diagnosis_num,data$pre2,auc=TRUE,ci=TRUE,smooth=T)

[0056] #Compare ROC curves

[0057] roc.test(roc1,roc2)

[0058] 4. Results

[0059] 1) We evaluated by calculating the receiver operating characteristic curve (ROC curve) and its area under it (AUC) and found that the five markers of SCC, CEA, CA199, CA153 and CA125 in the supernatant of uterine cell suspension can effectively distinguish patients with endometrial cancer from patients with benign endometrial lesions. The AUC of the model reached 0.918, which has significant diagnostic ability. In contrast, in blood testing, the AUC of the tumor marker model was 0.638 ( Figure 1 ). Therefore, this combined marker detection method based on endometrial supernatant may have a high application value in clinical practice.

[0060] 2) Model specific results

[0061] i. Uterine cell suspension supernatant SCC, CEA, CA199, CA153 and CA125 prediction model Call:

[0062] glm(formula=diagnosis_num~scc_tissue+cea_tissue+ca125_tissue+

[0063] ca153_tissue + ca199_tissue, family = binomial(), data = data)

[0064] Coefficients:

[0065] Estimate Std.Error z value Pr(>|z|)

[0066] (Intercept) -3.889e+00 1.109e+00 -3.506 0.000455***

[0067] scc_tissue 5.702e-02 1.766e-02 3.229 0.001243**

[0068] cea_tissue 3.793e-02 2.083e-02 1.821 0.068628.

[0069] ca125_tissue -1.363e-04 9.841e-05 -1.385 0.165941

[0070] ca153_tissue 4.379e-02 2.747e-02 1.594 0.110892

[0071] ca199_tissue -1.058e-05 3.071e-05 -0.345 0.730334

[0072] ---

[0073] Signif.codes: 0 ‘***’ 0.001 ‘**’ 0.01 ‘*’ 0.05 ‘.’ 0.1 ‘ ’ 1

[0074] (Dispersion parameter for binomial family taken to be 1)

[0075] ii. Serum SCC, CEA, CA199, CA153 and CA125 prediction models

[0076] Call:

[0077] glm(formula = diagnosis_num ~ scc_b + cea_b + ca125_b + ca153_b +

[0078] ca199_b,family=binomial(),data=data)

[0079] Coefficients:

[0080] Estimate Std.Error z value Pr(>|z|)

[0081] (Intercept)1.811202 1.125291 1.610 0.107

[0082] scc_b 0.103588 0.746598 0.139 0.890

[0083] cea_b -0.566952 0.365963-1.549 0.121

[0084] ca125_b -0.023716 0.014443-1.642 0.101

[0085] ca153_b -0.002567 0.046221-0.056 0.956

[0086] ca199_b 0.006360 0.010835 0.587 0.557

[0087] (Dispersion parameter for binomial family taken to be 1)

[0088] Diagnostic model based on tumor markers in the supernatant of uterine cell suspension

[0089] logit(p)=-3.889+0.05702×SCC_tissue+0.03793×CEA_tissue-0.0001363×CA125_tissue+0.04379×

[0090] CA153_tissue-0.00001058×CA199_tissue

[0091] Logit(p) is the logarithmic probability function, that is: logit(p) = ln(p / (1-p))

[0092] When applying this model for diagnosis:

[0093] a) Data collection: Obtain the data of various tumor markers in the supernatant of the patient's uterine cavity cell suspension.

[0094] b) Calculate logit(P): Substitute the collected values ​​into the model and calculate the logti(p) value.

[0095] c) Calculate the probability p: Use the logarithmic probability function to convert logit(p) into the actual probability value p, p = 1 / (1+e^(-logit(p)))

[0096] d) Diagnosis prediction: Based on the Youden index (0.5982494) of the supernatant model of intrauterine cell suspension as the threshold, if p>0.598, the patient is diagnosed as having endometrial cancer; otherwise, the patient is predicted to have benign endometrial lesions.

[0097] In order to fill the gap in endometrial cancer screening technology, we constructed a "uterine cavity micro-cell suspension supernatant detection" method, created a new body fluid detection system, and based on this detection technology, discovered new body fluid characteristic markers for endometrial cancer. It was found that the levels of markers such as CA125, CA153, CA199, CEA, SCC, HE4, FRT, AST, CK, LDH, GGT in the supernatant of uterine cavity micro-cell suspension were much higher than those in peripheral blood, especially the levels of CA125, CA153, CA199, CEA, and SCC in the supernatant of uterine cavity micro-cell suspension in the endometrial cancer group were significantly higher than those in the benign endometrial lesion group, which had predictive value. On this basis, we used CA125, CA153, CA199, CEA, and SCC intrauterine cell suspension supernatant detection data to construct an endometrial cancer risk prediction model called the "Endometrial Cancer Intrauterine Screening Model" through multifactorial logistic regression analysis, and developed an endometrial cancer screening diagnostic kit, which shows good clinical application potential in the field of endometrial cancer screening and diagnosis.

[0098] The above is only a preferred embodiment of the present invention. It should be pointed out that ordinary technicians in this technical field can make several improvements and supplements without departing from the method of the present invention. These improvements and supplements should also be regarded as the scope of protection of the present invention.

Claims

1. A high-risk population for endometrial cancer and a biomarker spectrum for predicting endometrial cancer, characterized in that: Includes reagents for measuring the following biomarkers in the supernatant of uterine cell suspension: CA125, CA153, CA199, CEA and SCC.

2. The endometrial cancer prediction model according to claim 1, characterized in that: Contains an operating manual, which contains the following contents: Collect the values ​​of CA125, CA153, CA199, CEA and SCC content; substitute the above values ​​into the scoring model; logit(p)=-3.889+0.05702×SCC_tissue+0.03793×CEA_tissue-0.0001363×CA125_tissue+0.04379×CA153_tissue-0.00001058×CA199_tissue If p>0.598, the patient is diagnosed as having endometrial cancer; otherwise, the patient is predicted to have benign endometrial lesions.

3. Use of a biomarker combination reagent in the preparation of a kit for predicting endometrial cancer, characterized in that: The biomarkers are composed of CA125, CA153, CA199, CEA and SCC, and the sample to be tested for the biomarkers is a reagent containing the supernatant content of uterine cavity cell suspension.

4. The use according to claim 3, characterized in that: The biomarker test sample is a reagent for the supernatant content of uterine cavity cell suspension of a high-risk group for endometrial cancer.

5. A kit for predicting endometrial cancer, characterized in that: The kit contains a biomarker combination reagent, wherein the biomarkers are composed of CA125, CA153, CA199, CEA, and SCC, and the sample to be tested for the biomarker is a reagent containing the supernatant content of a uterine cavity cell suspension.

6. The kit according to claim 5, characterized in that The biomarker test sample is a reagent for the supernatant content of uterine cavity cell suspension of a high-risk group for endometrial cancer.

7. Use of a biomarker combination reagent in the preparation of a kit for distinguishing endometrial cancer from benign endometrial lesions, characterized in that: The biomarkers are composed of SCC, CEA, CA199, CA153 and CA125, and the sample to be tested for the biomarkers is a reagent for the supernatant content of uterine cavity cell suspension.

8. The use according to claim 7, characterized in that: The biomarker test sample is a reagent for the supernatant content of uterine cavity cell suspension of a high-risk group for endometrial cancer.

9. A kit for distinguishing endometrial cancer from benign endometrial lesions, characterized in that: The kit contains a biomarker combination reagent, wherein the biomarker consists of SCC, CEA, CA199, CA153 and CA125, and the sample to be tested for the biomarker is a reagent containing the supernatant content of a uterine cavity cell suspension.

10. The kit according to claim 9, characterized in that The biomarker sample to be tested is a reagent for the supernatant content of uterine cavity cell suspension of a high-risk population for endometrial cancer. The kit also includes an operating instruction, which records the following contents: Collect the values ​​of CA125, CA153, CA199, CEA and SCC content; substitute the above values ​​into the scoring model; logit(p)=-3.889+0.05702×SCC_tissue+0.03793×CEA_tissue-0.0001363×CA125_tissue+0.04379×CA153_tissue-0.00001058×CA199_tissue If p>0.598, the patient is diagnosed as having endometrial cancer; otherwise, the patient is predicted to have benign endometrial lesions.

Citation Information

Cited By

  • A risk prediction model for endometrial carcinoma occurring from endometrial atypical hyperplasia and a construction method thereof

    CN122800181A